Jeanne Erdmann is an award-winning health and science writer based in Wentzville, Mo. A member of Association of
Health Care Journalists board of directors, she is the chair of the organization’s Freelance Committee. Her work has appeared in Discover, Women’s Health, Aeon, Slate, The Washington Post, Nature, Nature Medicine and other publications. You can follow her at @jeanne_erdmann.
Jeanne Erdmann
From this contributor
Analysis pins down prevalence of mental health conditions in autism
Eight mental health conditions occur unusually often in autistic people, a new analysis suggests.
Analysis pins down prevalence of mental health conditions in autism
Drug screen reveals potential treatments for Rett syndrome
An experimental leukemia drug and a chemical in black pepper ease breathing and movement problems in a mouse model of Rett syndrome.
Drug screen reveals potential treatments for Rett syndrome
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.